Valerio Therapeutics : announces the completion of a capital increase with cancellation of preferential subscription rights

About this update from Valerio Therapeutics

Previous Valerio Therapeutics announces the completion of a capital increase with cancellation of preferential subscription rightsVALERIO THERAPEUTICS ANNOUNCES THE COMPLETION OF A CAPITAL INCREASE WITH CANCELLATION OF PREFERENTIAL SUBSCRIPTION RIGHTS Paris (France), October 15, 2025 Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereinafter "Valerio Therapeutics" or the "Company", announces the completion of a capital increase with cancellation of preferential subscription rights for a total amount of €6,363,636.23, through the issuance of 138,339,918 new ordinary shares at a subscription price of €0.046 per new ordinary share, reserved for investors (the "Capital Increase") »). The Company raised a total amount of €6,363,636.23, including €3,499,999.99 in cash contributed by investors, and €2,863,636.20 by way of set-off of debt. On this occasion, Mr. Julien Miara, Chief Executive Officer, said: "The purpose of this capital increase is to supplement the Company's financial resources and enable it to finance the development of its platforms and internal pipelines while continuing the work initiated since the beginning of the year on the restructuring of its liabilities." Terms of the Capital Increase Based on the delegation granted by the Shareholders' Meeting of September 30, 2025, the Board of Directors of October 10, 2025, decided to proceed with a capital increase in the Company's capital, through the issuance of new ordinary shares with cancellation of preferential subscription rights for the benefit of categories of investors whose characteristics were determined by the Meeting. The subscription period for the Capital Increase as decided by the Board of Directors has been set from October 10 to October 20, 2025. Pursuant to the decisions of the Company's Board of Directors, the share capital was increased by a total nominal amount of €1,383,399.18 through the issuance of a total of 138,339,918 new ordinary shares, at a subscription price of €0.046 per share, representing a total subscription price of €6,363,636.23 (including issue premium). As the entire Capital Increase has been subscribed, the Chief Executive Officer, in accordance with the decisions of the Board of Directors, has confirmed the completion of the Capital Increase on October 15, 2025. The unit subscription price of the new shares used in connection with this transaction ...

View stock analysis, news, and events for Valerio Therapeutics